ATP sensitizes H460 lung carcinoma cells to cisplatin-induced apoptosis

Chemico-Biological Interactions

Volumn 184, Issue 3, 2010, Pages 338-345

  Swennen, Els L R ^a   Ummels, Vanessa ^a   Buss, Irina ^b   Jaehde, Ulrich ^b   Bast, Aalt ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Apoptosis; ATP; Chemotherapy; Cisplatin; Lung cancer; Multi drug resistance (MDR)

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; GLUTATHIONE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE S PHASE; CELL STRAIN; CELL STRAIN H460; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LD 50; LUNG CARCINOMA; MEMBRANE PERMEABILITY; PROTEIN DEPLETION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CISPLATIN; GLUTATHIONE TRANSFERASE; HUMANS; LACTATE DEHYDROGENASES; LUNG NEOPLASMS; PYRIMIDINES; RHODAMINES;

EID: 77949912837     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.02.011     Document Type: Article

References (50)

1. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
2. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
3. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478:23-43.
4. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007, 63:12-31.
5. Mure T., Sano K., Kitagawa T. Modulation of membrane permeability, cell proliferation and cytotoxicity of antitumor agents by external ATP in mouse tumor cells. Jpn. J. Cancer Res. 1992, 83:121-126.
6. Maymon R., Bar-Shira Maymon B., Cohen-Armon M., Holtzinger M., Leibovici J. Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines. Biochim. Biophys. Acta 1994, 1201:173-178.
7. Schneider C., Wiendl H., Ogilvie A. Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation. Biochim. Biophys. Acta 2001, 1538:190-205.
8. Conigrave A.D., van der Weyden L., Holt L., Jiang L., Wilson P., Christopherson R.I., Morris M.B. Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. Biochem. Pharmacol. 2000, 60:1585-1591.
9. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J. Cell. Physiol. 1983, 114:279-283.
10. Vandewalle B., Hornez L., Revillion F., Lefebvre J. Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium. Cancer Lett. 1994, 85:47-54.
11. Spungin B., Friedberg I. Growth inhibition of breast cancer cells induced by exogenous ATP. J. Cell. Physiol. 1993, 157:502-508.
12. Wang M.X., Ren L.M. Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine. Acta Pharmacol. Sin. 2006, 27:1085-1092.
13. Shabbir M., Ryten M., Thompson C., Mikhailidis D., Burnstock G. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int. 2008, 101:106-112.
14. Wiendl H.S., Schneider C., Ogilvie A. Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis. Biochim. Biophys. Acta 1998, 1404:282-298.
15. Volkl T., Ogilvie A., Neuhuber W. Cell death induced by uridine 5′-triphosphate (UTP) in contrast to adenosine 5′-triphosphate (ATP) in human epidermoid carcinoma cells (A-431). Cell. Physiol. Biochem. 2008, 22:441-454.
16. Fang W.G., Pirnia F., Bang Y.J., Myers C.E., Trepel J.B. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J. Clin. Invest. 1992, 89:191-196.
17. Shabbir M., Ryten M., Thompson C., Mikhailidis D., Burnstock G. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int. 2008, 101:352-359.
18. Janssens R., Boeynaems J.M. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br. J. Pharmacol. 2001, 132:536-546.
19. Shabbir M., Thompson C., Jarmulowiczc M., Mikhailidis D., Burnstock G. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int. 2008, 102:108-112.
20. Kitagawa T., Akamatsu Y. Modulation of passive permeability by external ATP and cytoskeleton-attacking agents in cultured mammalian cells. Biochim. Biophys. Acta 1983, 734:25-32.
21. Kitagawa T., Amano F., Akamatsu Y. External ATP-induced passive permeability change and cell lysis of cultured transformed cells: action in serum-containing growth media. Biochim. Biophys. Acta 1988, 941:257-263.
22. Schafer R., Sedehizade F., Welte T., Reiser G. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 285:L376-385.
23. White N., Burnstock G. P2 receptors and cancer. Trends Pharmacol. Sci. 2006, 27:211-217.
24. Hopfner M., Maaser K., Barthel B., von Lampe B., Hanski C., Riecken E.O., Zeitz M., Scherubl H. Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate. Int. J. Colorectal Dis. 2001, 16:154-166.
25. Hatta Y., Takahashi M., Enomoto Y., Takahashi N., Sawada U., Horie T. Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. Oncol. Rep. 2004, 12:1139-1142.
26. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Moscow) 2000, 65:95-106.
27. Estrela J.M., Obrador E., Navarro J., Lasso De la Vega M.C., Pellicer J.A. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat. Med. 1995, 1:84-88.
28. Bump E.A., Brown J.M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol. Ther. 1990, 47:117-136.
29. Carretero J., Obrador E., Esteve J.M., Ortega A., Pellicer J.A., Sempere F.V., Estrela J.M. Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. J. Biol. Chem. 2001, 276:25775-25782.
30. Gatti L., Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 2005, 111:127-148.
31. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
32. Lasso de la Vega M.C., Terradez P., Obrador E., Navarro J., Pellicer J.A., Estrela J.M. Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem. J. 1994, 298(Pt 1):99-105.
33. Palomares T., Bilbao P., del Olmo M., Castro B., Calle Y., Alonso-Varona A. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma. Melanoma Res. 1999, 9:233-242.
34. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
35. Kloft C., Appelius H., Siegert W., Schunack W., Jaehde U. Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther. Drug Monit. 1999, 21:631-637.
36. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
37. Vandeputte C., Guizon I., Genestie-Denis I., Vannier B., Lorenzon G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol. Toxicol. 1994, 10:415-421.
38. Habig W.H., Jakoby W.B. Assays for differentiation of glutathione S-transferases. Methods Enzymol. 1981, 77:398-405.
39. Coolen E.J., Arts I.C., Swennen E.L., Bast A., Stuart M.A., Dagnelie P.C. Simultaneous determination of adenosine triphosphate and its metabolites in human whole blood by RP-HPLC and UV-detection. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 864:43-51.
40. Kuo M.T., Chen H.H., Song I.S., Savaraj N., Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007, 26:71-83.
41. Kalayda G.V., Wagner C.H., Buss I., Reedijk J., Jaehde U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008, 8:175.
42. Kurokawa T., He G., Siddik Z.H. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother. Pharmacol. 2010, 65:427-436.
43. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181.
44. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 1991, 51:155-194.
45. Hercbergs A., Brok-Simoni F., Holtzman F., Bar-Am J., Leith J.T., Brenner H.J. Erythrocyte glutathione and tumour response to chemotherapy. Lancet 1992, 339:1074-1076.
46. Black S.M., Wolf C.R. The role of glutathione-dependent enzymes in drug resistance. Pharmacol. Ther. 1991, 51:139-154.
47. Chen H.H., Song I.S., Hossain A., Choi M.K., Yamane Y., Liang Z.D., Lu J., Wu L.Y., Siddik Z.H., Klomp L.W., Savaraj N., Kuo M.T. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol. Pharmacol. 2008, 74:697-704.
48. Meister A. Selective modification of glutathione metabolism. Science 1983, 220:472-477.
49. Mulder G.J., Ouwerkerk-Mahadevan S. Modulation of glutathione conjugation in vivo: how to decrease glutathione conjugation in vivo or in intact cellular systems in vitro. Chem. Biol. Interact. 1997, 105:17-34.
50. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:299-309.